A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine (APH204)
An Exploratory Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine
Sponsor: Asarina Pharma
This PHASE2 trial investigates Menstrual Migraine and is currently completed. Asarina Pharma leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Jun 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jun 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Jan 2020 [monthly]
Recruiting PHASE2
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asarina Pharma
- Aurevia
For direct contact, visit the study record on ClinicalTrials.gov .